IDH2 and central nervous system cancer: A major question emerging from the INDIGO trial is whether these results are applicable only to patients fulfilling the narrow inclusion criteria of the trial, or whether current data on IDH-mutant glioma allow a broader biological perspective and allow generalizability beyond the INDIGO population (ie, beyond grade 2 and non-enhancing IDHmt tumors).